Astria Therapeutics Inc. (ATXS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Astria Therapeutics Inc.

    NASDAQ: ATXS · Real-Time Price · USD
    7.52
    0.52 (7.43%)
    At close: Sep 05, 2025, 3:59 PM
    7.59
    0.93%
    After-hours: Sep 05, 2025, 07:44 PM EDT

    Astria Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a n/a
    Operating Income
    		 -111.56M -83.03M -53.5M -194.98M
    Interest Income
    		 17.36M 10.2M 1.72M 122K
    Pretax Income
    		 -94.26M -72.89M -51.83M -194.91M
    Net Income
    		 -94.26M -72.89M -51.83M -194.91M
    Selling & General & Admin
    		 34.45M 25.7M 19.24M 14.81M
    Research & Development
    		 77.11M 57.33M 34.26M 15.55M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 111.56M 83.03M 53.5M 30.36M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 -111.56M 83.03M 53.5M 30.36M
    Income Tax Expense
    		 n/a n/a n/a -164.74M
    Shares Outstanding (Basic)
    		 56.16M 30.12M 14.62M 8.93M
    Shares Outstanding (Diluted)
    		 56.16M 30.12M 14.62M 8.93M
    EPS (Basic)
    		 -1.68 -2.42 -3.55 -24.58
    EPS (Diluted)
    		 -1.68 -2.42 -3.55 -24.58
    EBITDA
    		 -94.26M -83.03M -53.5M -194.98M
    EBIT
    		 -94.26M -67.83M -51.83M -30.36M
    Depreciation & Amortization
    		 n/a -15.2M 228.49K -164.62M

    Add to Watchlist